Practical Insights Into Improving Adherence to Metformin Therapy in Patients With Type 2 Diabetes
- PMID: 31371854
- PMCID: PMC6640881
- DOI: 10.2337/cd18-0063
Practical Insights Into Improving Adherence to Metformin Therapy in Patients With Type 2 Diabetes
Abstract
IN BRIEF Adherence to metformin-based treatment regimens for type 2 diabetes is currently suboptimal due to a complex array of patient-, treatment-, and physician-related barriers, including physical and psychological swallowing difficulties associated with large tablets and gastrointestinal disturbances. Patients often avoid discussing these issues with their primary care providers, and delays in addressing them can lead to reduced glycemic control. This article reviews the issues commonly responsible for poor adherence to metformin and presents strategies to improve compliance, including shared decision-making and the use of different metformin formulations, including liquid metformin.
Similar articles
-
Empagliflozin/metformin fixed-dose combination: a review in patients with type 2 diabetes.Expert Opin Pharmacother. 2016 Dec;17(18):2471-2477. doi: 10.1080/14656566.2016.1258062. Epub 2016 Nov 22. Expert Opin Pharmacother. 2016. PMID: 27819159 Review.
-
Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.Pharmacoeconomics. 2004;22(6):389-411. doi: 10.2165/00019053-200422060-00005. Pharmacoeconomics. 2004. PMID: 15099124 Review.
-
Adherence to preventive medications: predictors and outcomes in the Diabetes Prevention Program.Diabetes Care. 2006 Sep;29(9):1997-2002. doi: 10.2337/dc06-0454. Diabetes Care. 2006. PMID: 16936143 Free PMC article. Clinical Trial.
-
Advantages of extended-release metformin in patients with type 2 diabetes mellitus.Postgrad Med. 2011 Jan;123(1):15-23. doi: 10.3810/pgm.2011.01.2241. Postgrad Med. 2011. PMID: 21293080 Review.
-
Epidemiologic Surveillance of Glycemic Response to a Scored, Breakable, Extended Release, Fixed Dose Combination of Gliclazide and Metformin in Persons with Type 2 Diabetes.J Assoc Physicians India. 2017 Jun;65(6):38-41. J Assoc Physicians India. 2017. PMID: 28782312
Cited by
-
Adherence and persistence rates of major antidiabetic medications: a review.Diabetol Metab Syndr. 2022 Jan 15;14(1):12. doi: 10.1186/s13098-022-00785-1. Diabetol Metab Syndr. 2022. PMID: 35033161 Free PMC article. Review.
-
Comparison of Insulins Glargine and Degludec in Diabetic Rhesus Macaques (Macaca mulatta) with CGM Devices.Comp Med. 2021 Jun 1;71(3):247-255. doi: 10.30802/AALAS-CM-20-000075. Epub 2021 May 25. Comp Med. 2021. PMID: 34034855 Free PMC article.
-
How drug onset rate and duration of action affect drug forgiveness.J Pharmacokinet Pharmacodyn. 2024 Jun;51(3):213-226. doi: 10.1007/s10928-023-09897-1. Epub 2024 Jan 10. J Pharmacokinet Pharmacodyn. 2024. PMID: 38198076
-
Curcumin Combination Chemotherapy: The Implication and Efficacy in Cancer.Molecules. 2019 Jul 10;24(14):2527. doi: 10.3390/molecules24142527. Molecules. 2019. PMID: 31295906 Free PMC article. Review.
-
Attitude, Knowledge, and Practices Regarding Prediabetes in Saudi Arabia: A Cross-Sectional Study on Family Medicine Residents.Cureus. 2024 Sep 12;16(9):e69300. doi: 10.7759/cureus.69300. eCollection 2024 Sep. Cureus. 2024. PMID: 39398787 Free PMC article.
References
-
- International Diabetes Federation IDF Diabetes Atlas. 8th ed. Brussels, Belgium, International Diabetes Federation, 2017. Available from www.diabetesatlas.org. Accessed 20 September 2018
-
- World Health Organization Adherence to Long-Term Therapies: Evidence for Action . Geneva, Switzerland, World Health Organization, 2003
-
- Cramer JA. A systematic review of adherence with medications for diabetes. Diabetes Care 2004;27:1218–1224 - PubMed
-
- Iglay K, Cartier SE, Rosen VM, et al. . Meta-analysis of studies examining medication adherence, persistence, and discontinuation of oral antihyperglycemic agents in type 2 diabetes. Curr Med Res Opin 2015;31:1283–1296 - PubMed